Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 3/20 | 0.46 |
| ▸ | HTR1B | P28222 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764050 | 0.86 | PARP1 (0.50) | PDE3BPDE3AHTR1ADRD2HTR2A | |
| SCHEMBL9197069 | 0.85 | PDE3B (0.48) | PDE3BPDE3AHTR1ADRD2HTR2A | |
| SCHEMBL554626 | 0.85 | PDE3B (0.48) | PDE3BPDE3AHTR1ADRD2HTR2A | |
| SCHEMBL8249215 | 0.84 | HTR1A (0.52) | PDE3BPDE3AHTR1ADRD2HTR2A | |
| SCHEMBL8185283 | 0.82 | PDE3B (0.46) | PDE3BPDE3AHTR1ADRD2HTR2A | |
| SCHEMBL13164143 | 0.82 | HTT (0.48) | HTR1AHTR1DHTR1BSLC6A4TSHR | |
| SCHEMBL4173618 | 0.82 | HTR1A (0.51) | PDE3BPDE3AHTR1ADRD2HTR2A | |
| SCHEMBL14072145 | 0.82 | HTR1A (0.34) | PDE3BPDE3AHTR1ADRD2HTR2A | |
| SCHEMBL13164150 | 0.81 | HTR1A (0.42) | HTR1AHTR1DHTR1BTSHRHTT | |
| SCHEMBL8199914 | 0.81 | PDE3B (0.45) | PDE3BPDE3AHTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008109180-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | PDE3B 605/4885PDE3A 767/4885HTR1A 2896/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PDE3B 605/4885PDE3A 767/4885HTR1A 2896/4885 |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PDE3B 550/4885PDE3A 605/4885HTR1A 3081/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PDE3B 605/4885PDE3A 767/4885HTR1A 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.